Kalbe Farma announced IDR 500 billion buyback of Kalbe Farma stock

Published on 10/09/2026 at 12:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 14.05 percent as net income fell 2.74 percent. Kalbe Farma stock costs EUR 0.04 on October 9, 2026 after EUR 0.04.

Key points in brief

Kalbe Farma announced an IDR 500 billion share buyback scheduled from September 17 to December 17, 2026.
First-half 2026 revenue rose 14.05 percent to IDR 19.48 trillion, while net income fell 2.74 percent to IDR 1.97 trillion.
Gross margin declined to 37.56 percent from 41.14 percent as imported input costs and currency pressure weighed on profitability.
Kalbe Farma stock was unchanged at EUR 0.04 at Lang & Schwarz on October 9, 2026, versus a prior close of EUR 0.04.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ID1000125107) was trading at EUR 0.04 at Lang & Schwarz on October 9, 2026 at 12:03 p.m. CEST, unchanged versus the prior close of EUR 0.04. According to Kontan on September 16, 2026, Kalbe Farma announced an IDR 500 billion buyback using internal funds, with the program scheduled from September 17 to December 17, 2026.

Three events set the backdrop

On July 31, 2026, Kalbe Farma reported second-quarter revenue of IDR 9.80 trillion and net income of IDR 890.54 billion, according to Investing.com. The finance statement shows the comparison with first-quarter revenue of IDR 9.68 trillion and net income of IDR 1.03 trillion.

On September 11, 2026, Kontan reported that first-half revenue reached IDR 19.48 trillion, up 14.00 percent year on year, while net income fell 2.80 percent to IDR 1.92 trillion. Gross margin stood at 37.60 percent, down 220 basis points from the prior-year period.

What does the buyback change?

The IDR 500 billion program gives the stock a capital-allocation angle while the operating picture remains mixed. InvestorTrust reported on September 16, 2026 that full execution could lift pro forma earnings per share to IDR 81.44 from IDR 80.51 for fiscal year 2025, while reducing interest income by IDR 8.40 billion.

The earnings effect is modest in absolute terms, but the contrast between sales and profit is more important for the current valuation debate. First-half revenue increased 14.05 percent to IDR 19.48 trillion, while net income declined 2.74 percent to IDR 1.97 trillion, according to Kontan on September 28, 2026. Cost of sales rose 20.97 percent to IDR 12.16 trillion, pushing gross margin down to 37.56 percent from 41.14 percent.

Dates for the program

The next concrete corporate date is December 17, 2026, when the maximum buyback window is scheduled to end. Kalbe Farma is funding the action internally, so the key operating question is whether share-count reduction can offset the IDR 8.40 billion interest-income effect while margin pressure persists.

Kalbe Farma stock stays unchanged

At Lang & Schwarz, Kalbe Farma stock was trading at EUR 0.04 on October 9, 2026 at 12:03 p.m. CEST, unchanged against the prior close of EUR 0.04. The Indonesia Stock Exchange quote was IDR 785 at 9:14 a.m. UTC on October 9, 2026, with a market capitalization of IDR 35.5 trillion and a daily volume of 56,612,700 shares.

The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.